New PET tracer may spot Hard-to-See neuroendocrine tumors
NCT ID NCT07132645
First seen Nov 01, 2025 · Last updated May 15, 2026 · Updated 29 times
Summary
This early-phase study is testing a new imaging agent called [68Ga]Ga-FAPI-04 to see where it collects in the bodies of 30 people with high-grade neuroendocrine tumors. The goal is to learn if this tracer can help detect these cancers better on PET/CT scans. Participants will receive the tracer and undergo imaging, with researchers measuring how much is taken up by tumors compared to normal tissues.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NEUROENDOCRINE TUMOR are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
University of Michigan Comprehensive Cancer Center
RECRUITINGAnn Arbor, Michigan, 48109, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.